Opportunities include identifying strategic regions for clinical trials, understanding enrollment trends, and analyzing trial success rates. The report aids investment strategies, saving time and cost ...

MRD testing showed weak trial-level correlation with progression-free survival in BTK inhibitor and venetoclax-based CLL studies.

Chronic lymphocytic leukemia (CLL) treatment options depend on your diagnosis. In earlier stages, “watchful waiting” may be recommended. More advanced CLL may require a combination of therapies.

Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...

Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for EGFR-Mutated Non–Small Cell Lung Cancer: Old or New Regimen? In the article that accompanies this editorial, ...

Analysis of readmission rates, length of stay and mortality among bone marrow transplant and CAR-T patients in a rural state. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

Bottom Line: Adding the investigational antibody ianalumab (VAY736) to ibrutinib (Imbruvica) allowed some patients with chronic lymphocytic leukemia (CLL) to discontinue daily therapy and potentially ...

Management attributes the increased net loss primarily to non-cash fair value adjustments of warrant liabilities from the ...